Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Akari Therapeutics stock

Own Akari Therapeutics stock in just a few minutes.

Akari Therapeutics, Plc is a biotechnology business based in the US. Akari Therapeutics shares (AKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Akari Therapeutics employs 9 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Akari Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AKTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Akari Therapeutics share price

Use our graph to track the performance of AKTX stocks over time.

Akari Therapeutics shares at a glance

Information last updated 2021-04-30.
52-week range$1.42 - $4.21
50-day moving average $2.60
200-day moving average $2.31
Wall St. target price$5.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.87

Buy Akari Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Akari Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Akari Therapeutics financials

Gross profit TTM $0
Return on assets TTM -101.26%
Return on equity TTM -363.75%
Profit margin 0%
Book value $0.24
Market capitalisation $80.4 million

TTM: trailing 12 months

Shorting Akari Therapeutics shares

There are currently 71,910 Akari Therapeutics shares held short by investors – that's known as Akari Therapeutics's "short interest". This figure is 276.4% up from 19,103 last month.

There are a few different ways that this level of interest in shorting Akari Therapeutics shares can be evaluated.

Akari Therapeutics's "short interest ratio" (SIR)

Akari Therapeutics's "short interest ratio" (SIR) is the quantity of Akari Therapeutics shares currently shorted divided by the average quantity of Akari Therapeutics shares traded daily (recently around 299625). Akari Therapeutics's SIR currently stands at 0.24. In other words for every 100,000 Akari Therapeutics shares traded daily on the market, roughly 240 shares are currently held short.

However Akari Therapeutics's short interest can also be evaluated against the total number of Akari Therapeutics shares, or, against the total number of tradable Akari Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akari Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Akari Therapeutics shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Akari Therapeutics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Akari Therapeutics.

Find out more about how you can short Akari Therapeutics stock.

Akari Therapeutics share dividends

We're not expecting Akari Therapeutics to pay a dividend over the next 12 months.

Have Akari Therapeutics's shares ever split?

Akari Therapeutics's shares were split on a 1:10 basis on 16 September 2015. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Akari Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Akari Therapeutics shares which in turn could have impacted Akari Therapeutics's share price.

Akari Therapeutics share price volatility

Over the last 12 months, Akari Therapeutics's shares have ranged in value from as little as $1.42 up to $4.21. A popular way to gauge a stock's volatility is its "beta".

AKTX.US volatility(beta: 1.23)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akari Therapeutics's is 1.2267. This would suggest that Akari Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Akari Therapeutics overview

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom. .

Frequently asked questions

What percentage of Akari Therapeutics is owned by insiders or institutions?
Currently 28.619% of Akari Therapeutics shares are held by insiders and 21.174% by institutions.
How many people work for Akari Therapeutics?
Latest data suggests 9 work at Akari Therapeutics.
When does the fiscal year end for Akari Therapeutics?
Akari Therapeutics's fiscal year ends in December.
Where is Akari Therapeutics based?
Akari Therapeutics's address is: 75/76 Wimpole Street, London, United Kingdom, W1G 9RT
What is Akari Therapeutics's ISIN number?
Akari Therapeutics's international securities identification number is: US00972G1085
What is Akari Therapeutics's CUSIP number?
Akari Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00972G108

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site